NI201000183A - Regímenes de dosificación de antiprogestina. - Google Patents

Regímenes de dosificación de antiprogestina.

Info

Publication number
NI201000183A
NI201000183A NI201000183A NI201000183A NI201000183A NI 201000183 A NI201000183 A NI 201000183A NI 201000183 A NI201000183 A NI 201000183A NI 201000183 A NI201000183 A NI 201000183A NI 201000183 A NI201000183 A NI 201000183A
Authority
NI
Nicaragua
Prior art keywords
progesterone
antagonist
dosage regimes
woman
antiprogestin
Prior art date
Application number
NI201000183A
Other languages
English (en)
Inventor
S Podolski Joseph
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of NI201000183A publication Critical patent/NI201000183A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención inmediata se relaciona con métodos para administrar composiciones que incluyen un antagonista del receptor de la progesterona. El antagonista de la progesterona puede ser una antiprogestina pura o un modulador selectivo de los receptores de la progesterona (selective progesterone receptor modulator, SPRM). En una aplicación preferida, el antagonista de la progesterona tiene poca afinidad por el receptor de glucocorticoides. En otra aplicación preferida, la administración del antagonista de la progesterona a una mujer no disminuye en forma sustancial los niveles de estrógeno de la mujer. Más preferentemente, el antagonista de la progesterona es CDB-4124.
NI201000183A 2008-04-28 2010-10-27 Regímenes de dosificación de antiprogestina. NI201000183A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4847208P 2008-04-28 2008-04-28

Publications (1)

Publication Number Publication Date
NI201000183A true NI201000183A (es) 2012-06-06

Family

ID=40751037

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000183A NI201000183A (es) 2008-04-28 2010-10-27 Regímenes de dosificación de antiprogestina.

Country Status (24)

Country Link
US (2) US8426394B2 (es)
EP (1) EP2293797B1 (es)
JP (1) JP5791499B2 (es)
KR (2) KR20130059442A (es)
CN (2) CN105616427A (es)
AR (1) AR071516A1 (es)
AU (1) AU2009241355B2 (es)
BR (1) BRPI0911563A2 (es)
CA (1) CA2722753C (es)
CL (1) CL2009001010A1 (es)
DK (1) DK2293797T3 (es)
EA (3) EA201990835A3 (es)
ES (1) ES2561810T3 (es)
IL (1) IL208844A0 (es)
ME (1) ME01123B (es)
MX (1) MX2010011272A (es)
MY (1) MY161059A (es)
NI (1) NI201000183A (es)
NZ (1) NZ589533A (es)
SG (1) SG10201408483QA (es)
TW (1) TWI477276B (es)
UA (1) UA102849C2 (es)
WO (1) WO2009134718A1 (es)
ZA (1) ZA201007529B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
HUP0900487A2 (hu) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2471537A1 (en) 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
NZ702467A (en) * 2012-05-31 2016-07-29 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
CA2888377C (en) * 2012-11-02 2021-02-02 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
HU230381B1 (hu) * 2014-02-17 2016-03-29 Richter Gedeon Nyrt Ipari eljárás szteroid intermedier előállítására
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
DE3486448T2 (de) 1983-11-14 1997-10-09 Columbia Lab Inc Bioadhäsive Mittel
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
ATE212833T1 (de) * 1993-11-16 2002-02-15 Schering Ag Verwendung von stickstoffoxid-synthase-substrat und/oder -donor oder stickstoffoxidhemmer zur herstellung von medikamenten zur behandlung von störungen der uterinen kontraktilität
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
MX9603889A (es) * 1995-02-02 1997-04-30 Schering Ag Antagonistas de progesterona para la produccion de agente farmaceuticos para el tratamiento de sangrado uterino disfuncional.
JP4260886B2 (ja) * 1996-05-01 2009-04-30 アメリカ合衆国 新規の抗プロゲステロンとしての２１―置換プロゲステロン誘導体
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO1998008471A1 (en) 1996-08-30 1998-03-05 The Population Council, Inc. Vaginal application mifepristone
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
DE60134126D1 (de) * 2000-03-17 2008-07-03 Us Gov Health & Human Serv 17-alpha-substituierte-11-beta-substituierte-4-aryl und 21-substituierte 19-norpregnadienedione mit antigestagener aktivität
IN191020B (es) 2000-03-28 2003-09-13 Dabur Res Foundation
KR100464159B1 (ko) 2000-04-03 2005-01-03 아스텐존슨 인코포레이티드 예비 권축형 연락부 부재
SI1328276T1 (sl) 2000-10-18 2006-04-30 Schering Ag Uporaba antiprogestinov za profilakso in zdravljenje bolezni, odvisnih od hormonov
BR0211067A (pt) 2001-07-09 2006-10-31 Zonagen Inc métodos e materiais para o tratamento de deficiência de testosterona em homens
EP1620060B1 (en) 2003-04-29 2010-03-24 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
EP1593376A1 (en) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
BRPI0513141A (pt) * 2004-07-09 2008-04-29 Population Council Inc composição para anel vaginal, e, processo de contracepção a longo prazo
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
DE102005028970A1 (de) * 2005-06-22 2006-12-28 Siemens Ag Piezoakter mit gesteigertem Hubvermögen
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
US8173626B2 (en) 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
WO2008067086A2 (en) 2006-10-24 2008-06-05 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
EP2125858A2 (en) * 2007-01-17 2009-12-02 Repros Therapeutics Inc. Pharmaceutically acceptable salts of 11-(4-aminophenyl)-19-norpregna-4,9(10)-diene-3,20-dione derivatives
JP5379121B2 (ja) 2007-04-05 2013-12-25 ユニバーシティ・オブ・カンザス プルランを含む速溶性医薬組成物
PL2148681T3 (pl) 2007-04-20 2016-09-30 Selektywny modulator progesteronu w leczeniu krwawienia z macicy
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
JP5992330B2 (ja) 2009-09-29 2016-09-14 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ 物質を投与するための子宮内電子カプセル

Also Published As

Publication number Publication date
EP2293797B1 (en) 2015-11-11
ZA201007529B (en) 2011-07-27
MY161059A (en) 2017-04-14
EA032646B1 (ru) 2019-06-28
AU2009241355A1 (en) 2009-11-05
EA201401347A1 (ru) 2015-07-30
JP2011518845A (ja) 2011-06-30
CL2009001010A1 (es) 2009-06-19
DK2293797T3 (en) 2016-01-11
TWI477276B (zh) 2015-03-21
NZ589533A (en) 2012-06-29
WO2009134718A1 (en) 2009-11-05
ES2561810T3 (es) 2016-03-01
IL208844A0 (en) 2011-01-31
EA201071249A1 (ru) 2011-08-30
EP2293797A1 (en) 2011-03-16
AU2009241355B2 (en) 2013-11-14
SG10201408483QA (en) 2015-02-27
US20110046098A1 (en) 2011-02-24
TW200950786A (en) 2009-12-16
US8735381B2 (en) 2014-05-27
KR20130059442A (ko) 2013-06-05
US20130289008A1 (en) 2013-10-31
ME01123B (me) 2013-03-20
US8426394B2 (en) 2013-04-23
KR20110014162A (ko) 2011-02-10
CN105616427A (zh) 2016-06-01
UA102849C2 (ru) 2013-08-27
JP5791499B2 (ja) 2015-10-07
CA2722753C (en) 2018-07-03
WO2009134718A8 (en) 2010-09-23
CN102014923A (zh) 2011-04-13
BRPI0911563A2 (pt) 2016-07-12
EA201990835A3 (ru) 2019-12-30
EA201990835A2 (ru) 2019-08-30
MX2010011272A (es) 2010-12-21
CA2722753A1 (en) 2009-11-05
AR071516A1 (es) 2010-06-23

Similar Documents

Publication Publication Date Title
NI201000183A (es) Regímenes de dosificación de antiprogestina.
AR117670A2 (es) Modulador del receptor de andrógeno y sus usos
PE20061415A1 (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
CL2009001560A1 (es) Composición nutricional para bebes que comprende una mezcla de oligosacáridos compuesta de oligosacáridos n-acetilados, galactooligosácaridos y oligosacáridos sialilados; y su uso.
CL2011003172A1 (es) Composicion farmaceutica que comprende a) un excepiente, b) al menos un precursor de esteroides sexuales, c) al menos un modulador selectivo del receptor de estrogenos o una antiestrogeno y no contiene una progestina y/o un estrogeno; kit farmaceutico; y uso para reducir o eliminar sofocos, sintomas vasomotores y sudores nocturnos.
ECSP077236A (es) Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos
UY31622A1 (es) Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2
EA201071291A3 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
CO6290752A2 (es) Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina
ECSP077233A (es) Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos
GT201700270A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
UY30109A1 (es) Formas farmacológicas en forma de película para usar en la cavidad bucal (obleas)
PE20181523A1 (es) Tratamiento de lupus nefritis usando laquinimod
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
CR9468A (es) Oblea que contiene hormonas esteroides
TW200738269A (en) Oral delivery of therapeutic agents using tight junction agonists
AR084707A1 (es) Una composicion farmaceutica de combinacion para tratar enfermedades o condiciones asociados al sistema cardiovascular
CL2017002920A1 (es) Régimen modulador selectivo de los receptores de progesterona (sprm).
SV2009003168A (es) Derivados de oxazolidona como moduladores pr
GT200600272A (es) Moduladores no esteroides de receptores de progesterona
CL2011001207A1 (es) Extruidos que contienen al menos una sustancia farmacéuticamente activa en forma de agujas, tal que la relación entre el tamaño de partículas de la sustancia farmacéuticamente activa con forma de agujas y el diámetro de la cadena es de al menos 1:20; composición farmacéutica; y su uso para preparar medicamentos.
UY32005A (es) Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a